BRITISH CANNABIS, a private Cannabidol producer, is the current leader in the UK’s CBD sweepstakes. A total of 310 products that are associated with BRITISH CANNABIS were recently advanced to regulators This has been revealed by an analysis of a list published earlier this month by Food Standards Agency (FSA).

The preliminary approval was granted to 75 products that were submitted by the Berkshire-based business, and 235 submitted jointly with other businesses. FSA preliminarily approved 3,536 items as new or novel foods according to the table, which was published on March 31

RX Pharmatech Ltd. (Bradford, West Yorkshire), which has ties with U.S. This was the second highest total RX Pharmatech submitted both 116 and 157 products in tandem with other producers.

According to the Association for the Cannabinoid Industry, the UK’s market for CBD products was valued at PS690million (EUR814.5million; $905.7million) in 2021. According to ACI, CBD sales in the UK more than doubled between 2019 and 2021, this makes the UK the second-largest consumer market outside of the USA.

Companies remaining

The FSA approved products for 374 companies. Some companies submitted applications separately, others as part of joint applications with other producers. Others filed jointly and independently. A total of 70 CBD applications were submitted to FSA.

Products that were on the list may still be available for sale. However, products that did not pass FSA scrutiny must be removed from market. FSA has stated that approvals are preliminary, products could be eliminated during later stages.

The majority of these products were moved to pre-validation (“awaiting evidence”) status, which is the second stage in the FSA’s novel foods approval process. Fifty-seven of the products are now in the last stage and await FSA’s final decision.

Clearance is what you seek

FSA’s novel foods approval process is designed to clarify a growing gray market, which has seen thousands of cannabidol products appear in retail outlets over recent years. The products must have been in circulation before February 13, 2020 to be eligible for agency consideration. Any products added after that date are not eligible to be considered.

British Cannabis products were presumably obtained from a consortium established by the ACI. ACI declined to provide information on the number of products that were sent through its consortium. It also refused to disclose the names or numbers of the applicants (FPs) submitted by the companies. ACI’s members list at least 628 products, which includes British Cannabis, among those that advanced.

Applications of EIHA

RX Pharmatech submitted its products to the European Industrial Hemp Association (EIHA), which saw 1,992 CBD products be preliminarily accepted, representing roughly 56%.

EIHA Projects GmbH received products submitted by 193 companies The EIHA saw 1,992 CBD products preliminarily approve, accounting for about 56%.. The applications covered both full-spectrum extracts (835) and isolates (1,157).

A quick look at the top companies

There were 374 companies involved in the entire list of 3,536 products, here are five top-five based on the number approved by FSA.

British Cannabis

British cannabis oil, an independent vertically integrated producer of cannabis, Cannabidol and other cannabinoid product, was founded in 2015.The company produces its own products and supplies brands on a white label basis. British Cannabis maintains a research farm in Portugal and has its own lab, manufacturing plant, warehouse, and dispatch operations. The company claims to be able to ship more than 50,000 CBD oil bottles in the first half (2021), between two of its largest white label clients. BRITISH CANNABIS announced its intention to invest in a new facility. It will include an ISO-accredited cannabis analytics testing lab and a cosmetics line. It has the potential to triple its current capacity. One of the 35 UK government “chemist rings trial” testing labs is used to measure CBD and cannabinoid levels in commercial products.

Associated principals : Thomas Whettem CEO & Founder, David Ralston, Managing director

RX Pharmatech Ltd

RX Pharmatech Ltd. doesn’t appear to have a website, and very little public information about it is available Other sources indicate that the company started in May 2016. RX Pharmatech sells bulk isolates from and distillates that are produced by GVB Biopharma (Las Vegas, Nevada), USA. RX Pharmatech have also been a party the second-highest FSA product list. GVB, Las Vegas, Nevada, USA, claimed in a Press Release April 7, 2020 that it is also the largest supplier to producers of white-label formulations for oral vape liquids. GVB claimed that it sources its raw materials from a U.S. farmers cooperative. GVB’s website indicates that there is a UK office located in Doncaster, Yorkshire. GVB only has one investor, Decathlon Capital Partners GVB has one investor: Decathlon Kapital Partners, a growth equity business based out of Park City, Utah. GVB claims operations in Europe (location not identified) and Bogota Colombia. GVB Biopharma joined Medicaleaf Ltd. and Cheltenham, Gloucestershire as part of its partnership with RX Pharmatech to submit three products to the FSA. GVB Biopharma is said to be in an strategic relationship with Sonder Fulfillment. This division of Golden Triangle Ventures is a Las Vegas-based pennystock operator.

Principals associated with RX Pharmatech Ltd. Dominic James Bartle is the director and Damien Jonathan Bove is the director. GVB Biopharma Phillip Swindells is the CEO and co-founder. Jack Feldman is president & Co-founder. Hugh Kinsman is CFO.

Mile High Labs

Mile High Labs in Broomfield, Colorado is a supplier for CBD, CBN and CBG. Mile High reported in 2019 it had raised $100,000,000 in funding in two rounds. Mile High has an extraction plant that uses raw materials from contracted CBD hemp growers in America. According to the company’s website, there is also a office in Belfast, Northern Ireland.

Associated principals Jonathan Hilley CEO, Ryan Keeler COO, Jodi Gatica VP Quality, Danny Moses, Investor.

Taylor Mammon Ltd

Taylor Mammon Ltd. describes itself as a white label manufacturer and cannabidol distributor, based in Welwyn Garden City. The company is owned by Kentucky-based parent GenCanna. Also known as OGGUSA Inc., GenCanna was famously bankrupted in 2020. There were a lot of creditors who claimed the company owed them between $100 to 500 million. In May 2020, GenCanna was sold to MGG Investment Group (New York), a private direct lender. GenCanna purchased Taylor Mammon’s UK-based cannabidol Capital in the last year.

Associated principals : Taylor Mammon – Alex Taylor, cofounder; James Taylor chief commercial officer; Nathan Wogman cofounder and managing director. GenCanna/OGGUSA Inc. – Andrew Barnett, CEO; Hassan Akhtar, managing director, Europe.

Sativa Wellness Group

Goodbody Health Inc is now known. However, it has submitted its novel foods application under Sativa Wellness. It is an OTC traded manufacturer of approximately 20 CBD products. This includes oils, capsules, and gummies There are also laboratories in the UK and Poland for testing CBD products.Goodbody/Sativa Wellness has its headquarters in Vancouver, British Columbia. In 2020, the most recent year that public financial reports are available, the company reported a loss close to $6.5 million (PS5,000,000). Goodbody shares are currently trading at approximately $0.05 (5cents). Goodbody’s UK affiliate, PhytoVista Laboratories received a controlled drugs license last month (April 2022).

Associated principals (Goodbody Health Inc.): Geremy Tom, Founder & Executive Chair; Marc Howells CEO; Anne Tew CFO and Corporate Secretary.

130620cookie-checkcbd oil

Leave a Reply

Your email address will not be published. Required fields are marked *

Registration option not enabled in your general settings.